Characterization and screening of IgG binding to the neonatal Fc receptor

mAbs

Volumn 6, Issue 4, 2014, Pages 928-942

  Neuber, Tobias ^a   Frese, Katrin ^a   Jaehrling, Jan ^a   Jäger, Sebastian ^a   Daubert, Daniela ^a   Felderer, Karin ^a   Linnemann, Mechthild ^a   Höhne, Anne ^a   Kaden, Stefan ^a   Kölln, Johanna ^a,b   Tiller, Thomas ^a   Brocks, Bodo ^a   Ostendorp, Ralf ^a   Pabst, Stefan ^a  

^a MORPHOSYS AG   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Biolayer interferometry; Equilibrium dissociation constant; Monoclonal antibody; Neonatal Fc receptor; pH dependent binding; Surface plasmon resonance; Ylanthia

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; NEONATAL FC RECEPTOR; UNCLASSIFIED DRUG; COMPLEMENTARITY DETERMINING REGION; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTIBODY LIBRARY; ANTIGEN BINDING; ARTICLE; BIOLAYER INTERFEROMETRY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; HUMAN; INTERFEROMETRY; LIGHT CHAIN; MACACA FASCICULARIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PH; RAT; SURFACE PLASMON RESONANCE; ANIMAL; CELL LINE; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; COMPLEMENTARITY DETERMINING REGIONS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MACACA FASCICULARIS; MICE; PROTEIN BINDING; RATS; RECEPTORS, FC; RECOMBINANT PROTEINS;

EID: 84903779367     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28744     Document Type: Article

References (61)

1. Reichert JM. Antibodies to watch in 2014. MAbs 2013; 6:5-14; PMID:24284914
2. Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013; 5:1-4; PMID:23254906; http://dx.doi.org/10.4161/mabs.22976
3. Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 2012; 14:554-8; PMID:22610647; http://dx.doi.org/10.1208/s12248-012-9369- y
4. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155
5. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000; 18:739-66; PMID:10837074; http://dx.doi.org/10.1146/annurev.immunol.18.1.739
6. Kacskovics I, Cervenak J, Erdei A, Goldsby RA, Butler JE. Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies. MAbs 2011; 3:431-9; PMID:22048692; http://dx.doi.org/10.4161/mabs.3.5.17023
7. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective - FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006; 27:343-8; PMID:16731041; http://dx.doi.org/10.1016/j.it. 2006.05.004
8. Kim J, Bronson CL, Hayton WL, Radmacher MD, Roopenian DC, Robinson JM, Anderson CL. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol 2006; 290:G352-60; PMID:16210471; http://dx.doi.org/10.1152/ajpgi.00286.2005
9. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157-9; PMID:20081867; http://dx.doi.org/10.1038/nbt.1601
10. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs 2011; 3:422-30; PMID:22048693; http://dx.doi.org/10.4161/mabs.3.5.16983
11. Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 1976; 71:666-9; PMID:11223; http://dx.doi.org/10.1083/jcb.71.2.666
12. Martin WL, West AP Jr., Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867-77; PMID:11336709; http://dx.doi.org/10.1016/S1097-2765(01)00230-1
13. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994; 372:379-83; PMID:7969498; http://dx.doi.org/10.1038/372379a0
14. West AP Jr., Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 2000; 39:9698-708; PMID:10933786; http://dx.doi.org/10.1021/ bi000749m
15. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
16. Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 1999; 29:2819-25; PMID:10508256; http://dx.doi.org/10.1002/(SICI) 1521-4141(199909)29:09〈2819::AIDIMMU2819〉3.0.CO;2-6
17. Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A 2006; 103:18709-14; PMID:17116867; http://dx.doi.org/10.1073/pnas.0606304103
18. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; http://dx.doi.org/10. 1093/intimm/13.12.1551
19. Magistrelli G, Malinge P, Anceriz N, Desmurs M, Venet S, Calloud S, Daubeuf B, Kosco-Vilbois M, Fischer N. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Methods 2012; 375:20-9; PMID:21939661; http://dx.doi.org/10.1016/j.jim. 2011.09.002
20. Zhou J, Mateos F, Ober RJ, Ward ES. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J Mol Biol 2005; 345:1071-81; PMID:15644205; http://dx.doi.org/10.1016/j.jmb.2004.11.014
21. Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor (FcRn) show dramatic differences in immunoglobulin G (IgG) and albumin binding. J Biol Chem 2010; 285:4826-36; http://dx.doi.org/10.1074/jbc.M109.081828
22. Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs 2013; 5:1-9; PMID:23549129; http://dx.doi.org/10.4161/mabs.23836
23. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39:1469-77; PMID:21610128; http://dx.doi.org/10.1124/dmd.111.039453
24. Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem 2012; 287:22927-37; PMID:22570488; http://dx.doi.org/10.1074/jbc.M112. 355131
25. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-71; PMID:19494290; http://dx.doi.org/10.4049/jimmunol.0804182
26. Martin WL, Bjorkman PJ. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 1999; 38:12639-47; PMID:10504233; http://dx.doi.org/10.1021/bi9913505
27. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385-92; PMID:20159773; http://dx.doi.org/10.1093/protein/gzq009
28. Andersen JT, Justesen S, Berntzen G, Michaelsen TE, Lauvrak V, Fleckenstein B, Buus S, Sandlie I. A strategy for bacterial production of a soluble functional human neonatal Fc receptor. J Immunol Methods 2008; 331:39-49; PMID:18155020; http://dx.doi.org/10.1016/j.jim.2007.11.003
29. Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, et al. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays. J Immunol Methods 2011; 365:132-41; PMID:21185301; http://dx.doi.org/10.1016/j.jim.2010.12.014
30. Kelley RF, Meng YG. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. Methods Mol Biol 2012; 901:277-93; PMID:22723108; http://dx.doi.org/10.1007/978-1-61779-931-0-18
31. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176:346-56; PMID:16365427
32. Mathur A, Arora T, Liu L, Crouse-Zeineddini J, Mukku V. Qualification of a homogeneous cellbased neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics. J Immunol Methods 2013; 390:81-91; PMID:23384837; http://dx.doi.org/10.1016/j.jim.2013.01. 011
33. Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksaritanont T, et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol 2009; 46:1878-82; PMID:19269032; http://dx.doi.org/10.1016/j.molimm. 2009.02.002
34. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al. Competition for FcRn-mediated transport gives rise to short halflife of human IgG3 and offers therapeutic potential. Nat Commun 2011; 2:599; PMID:22186895; http://dx.doi.org/10.1038/ncomms1608
35. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171-80; PMID:12391234
36. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-24; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
37. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35:86-94; PMID:17050651; http://dx.doi.org/10.1124/dmd.106.011734
38. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20:460-70; PMID:18656541; http://dx.doi.org/10.1016/j. coi.2008.06.012
39. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S. Pharmacokinetics of humanized monoclonal antitumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38:600-5; PMID:20071453; http://dx.doi.org/10.1124/dmd.109.031310
40. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13:1-110; PMID:4186070
41. Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010; 29:48-52; PMID:20430307; http://dx.doi.org/10.1016/j.sder.2010.02.001
42. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968-76; PMID:20083659; http://dx.doi.org/10.4049/jimmunol.0903296
43. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 2007; 282:1709-17; PMID:17135257; http://dx.doi.org/10.1074/jbc.M607161200
44. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203-7; PMID:20953198; http://dx.doi.org/10.1038/nbt. 1691
45. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. MAbs 2011; 3:243-52; PMID:21406966; http://dx.doi.org/10.4161/mabs.3.3.15234
46. Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, Berenguer M, Poujol D, Stehle J, Stark Y, et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs 2013; 5:1-26; PMID:23571156; http://dx.doi.org/10. 4161/mabs.24218
47. Abdiche Y, Malashock D, Pinkerton A, Pons J. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem 2008; 377:209-17; PMID:18405656; http://dx.doi.org/10.1016/j.ab.2008.03.035
48. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 2011; 48:860-6; PMID:21256596; http://dx.doi.org/10.1016/j.molimm.2010.12.009
49. Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL Jr. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 2008; 47:5088-100; PMID:18407665; http://dx.doi.org/10.1021/bi702238b
50. Andersen JT, Dee Qian J, Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol 2006; 36:3044-51; PMID:17048273; http://dx.doi.org/10.1002/eji.200636556
51. Gurbaxani BM, Morrison SL. Development of new models for the analysis of Fc-FcRn interactions. Mol Immunol 2006; 43:1379-89; PMID:16183124; http://dx.doi.org/10.1016/j.molimm.2005.08.002
52. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23:1283-8; PMID:16186811; http://dx.doi.org/10.1038/nbt1143
53. Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos 2012; 40:1545-55; PMID:22584253; http://dx.doi.org/10.1124/dmd.112.045864
54. Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012; 4:753-60; PMID:23778268; http://dx.doi.org/10.4161/mabs.22189
55. Van den Brulle J, Fischer M, Langmann T, Horn G, Waldmann T, Arnold S, Fuhrmann M, Schatz O, O'Connell T, O'Connell D, et al. A novel solid phase technology for high-throughput gene synthesis. Biotechniques 2008; 45:340-3; PMID:18778261; http://dx.doi.org/10.2144/000112953
56. Rothe C, Urlinger S, Löhning C, Prassler J, Stark Y, Jäger U, Hubner B, Bardroff M, Pradel I, Boss M, et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 2008; 376:1182-200; PMID:18191144; http://dx.doi.org/10.1016/j.jmb.2007.12.018
57. Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001; 38:1-8; PMID:11483205; http://dx.doi.org/10.1016/S0161-5890(01) 00050-5
58. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wölle J, Plückthun A, Virnekäs B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000; 296:57-86; PMID:10656818; http://dx.doi.org/10.1006/jmbi.1999.3444
59. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
60. Ewert S, Huber T, Honegger A, Plückthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325:531-53; PMID:12498801; http://dx.doi.org/10.1016/S0022-2836(02)01237-8
61. Cho MS, Yee H, Chan S. Establishment of a human somatic hybrid cell line for recombinant protein production. J Biomed Sci 2002; 9:631-8; PMID:12432229; http://dx.doi.org/10.1007/BF02254991